Summary & Overview
HCPCS J2360: Orphenadrine Injection, Up to 60 mg
HCPCS Level II code J2360 represents the injectable formulation of orphenadrine citrate, up to 60 mg. This drug-administration code is used when orphenadrine is delivered by injection in ambulatory or acute-care settings to provide muscle relaxation or symptomatic relief as clinically indicated. Nationally, reporting of injectable medication codes like J2360 matters for claims processing, pharmacy billing, and monitoring utilization of parenteral therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J2360 is classified and billed, typical places of service, and the clinical context for injectable orphenadrine. The publication outlines benchmarking metrics and payer coverage considerations where available, summarizes relevant policy updates affecting injectable drug claims, and clarifies common billing practices tied to medication administration lines.
This briefing is intended to help revenue cycle professionals, billers, and policy analysts understand the role of HCPCS Level II code J2360 in billing workflows, payer interactions, and coding documentation for injectable medication services. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code J2360 describes an injection of orphenadrine citrate, up to 60 mg. This code is used to report administration of orphenadrine as an injectable medication for its clinical indications.
Service type: Medication administration (injectable)
Typical site of service: Outpatient clinics, physician offices, emergency departments, and other ambulatory care settings where injectable medications are administered.
Clinical & Coding Specifications
Clinical Context
A typical scenario involves an adult patient presenting to an outpatient infusion clinic, urgent care, or emergency department with acute severe muscle spasm or spasticity after musculoskeletal strain, low back injury, or acute neurologic exacerbation. The clinician assesses the need for short‑acting systemic muscle relaxation and elects to administer an intramuscular or intravenous dose of orphenadrine citrate (J2360, up to 60 mg) when oral therapy is not tolerated, not feasible, or rapid onset is required. The clinical workflow includes verification of indications and allergies, medication reconciliation, informed consent, preparation and labeling of the syringe or IV infusion, performance of injection under appropriate aseptic technique, monitoring for sedation, anticholinergic effects, blood pressure and heart rate, and documentation of drug, dose, route, site, lot number and expiration, and patient response. Typical sites of service include outpatient infusion centers, physician offices, urgent care clinics, and emergency departments. Common clinical personnel involved are the prescribing physician (e.g., physiatrist, emergency medicine physician, or orthopedic surgeon), a registered nurse or licensed practical nurse to administer the injection, and billing/coding staff to append appropriate HCPCS J2360 with relevant modifier(s).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |